STTR Phase II: Development of a Lead Optimization Chip for Drug Discovery

该奖项是根据2009年美国复苏和再投资法案（公法111-5）资助的。该小企业技术转让（STTR）第二阶段项目将致力于多酶先导优化芯片（Multizyme Chip）的进一步开发和商业化，用于高通量生成先导化合物类似物，并结合基于细胞的筛选，用于快速鉴定生物活性衍生物。这种能力直接影响药物发现的关键瓶颈;即，有效优化先导化合物以开发具有最佳药理学性质的药物。Solidus Biosciences，Inc.提出了将联合收割机六种生物催化与药理学筛选相结合，以提供针对细胞特异性靶标的生物活性化合物的快速鉴定，这是先导物优化的新范例。此外，Multizyme Chip平台将非常适合相关行业的铅优化，包括农用化学品，化妆品和药妆品。因此，Solidus技术将提高制药、化妆品和化工行业的竞争力和效率，并将成为新的和改进的商业产品的丰富来源。这项研究的更广泛影响是Solidus Biosciences将在生产更好和更安全的药物方面取得进步，降低开发这些药物的成本，并提高制药行业的整体效率。Solidus将为制药和生物技术公司提供Multizyme芯片，以促进其铅优化计划，特别是涉及天然产品衍生和复杂合成小分子铅的计划。第二阶段开发的低温保存技术将使第一阶段生产的芯片和芯片处理设备能够销售，并将使Solidus技术平台无缝渗透到公司的目标市场。

This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).This Small Business Technology Transfer (STTR) Phase II project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products.The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets.